TrialOncotarget2015

Immunological response and overall survival in a subset of advanced renal cell carcinoma patients from a randomized phase 2/3 study of naptumomab estafenatox plus IFN-α versus IFN-α.

Eyad Elkord et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.